NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (DRC) has been registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. This registration is a significant milestone for the company, as it formally records the trial's design and objectives, enhancing transparency and credibility.
The company previously received local regulatory approval from ACOREP to begin the trial. According to the announcement, NV-387 has been delivered to the clinical trial site in Ituri province, with first patient dosing anticipated within one to two weeks, barring outbreak-related impediments. The adaptive trial will begin with a single-arm safety and dose run-in before progressing to a randomized, controlled, open-label efficacy evaluation.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. This mechanism is intended to interfere with the virus's ability to attach to and enter host cells, potentially offering a novel approach to treating multiple viral infections. The drug is also being evaluated in a Phase II clinical trial for Mpox in the DRC, underscoring its broad-spectrum potential.
The registration of this trial is particularly important because Ebola virus disease (EVD) remains a serious public health threat in Africa, with frequent outbreaks causing high mortality rates. Current treatments are limited, and the availability of an oral therapeutic like NV-387 could significantly improve patient outcomes, especially in resource-limited settings where intravenous therapies are challenging to administer. The trial's location in the DRC, a country that has experienced multiple Ebola outbreaks, highlights the urgent need for effective treatments.
NanoViricides' platform technology is based on the TheraCour nanomedicine technology, which the company licenses from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license to this technology for several drugs targeting specific human viral diseases, including Ebola/Marburg viruses. The company's lead drug candidate, NV-387, is also being developed for other respiratory viral infections such as RSV, COVID-19, and influenza, as well as other indications.
The initiation of this trial could have broader implications for the field of antiviral therapy. If successful, NV-387 could become a vital tool in pandemic preparedness and outbreak response, given its oral formulation and broad-spectrum activity. Moreover, the adaptive trial design allows for efficient evaluation of safety and efficacy, potentially accelerating the drug's development timeline.
As with any clinical trial, there are risks and uncertainties. The company has noted that the path to drug development is extremely lengthy and requires substantial capital. There can be no assurance that NV-387 will demonstrate sufficient effectiveness and safety in human trials. However, the registration and planned dosing represent a proactive step forward in addressing a critical unmet medical need.
For more information about the trial and NanoViricides, visit the company's newsroom at https://nnw.fm/NNVC.
